Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

T Cell Inflamed Gene Expression Profiling Score-guided Anti PD-1 Therapy (Tislelizumab Monotherapy) for Refractory Solid Cancer Patients Unexposed to Immunotherapy

NCT07300891 is registered in ClinicalTrials.gov with Samsung Medical Center as lead sponsor.

NCT NCT07300891
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07300891 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
T Cell Inflamed Gene Expression Profiling Score-guided Anti PD-1 Therapy (Tislelizumab Monotherapy) for Refractory Solid Cancer Patients Unexposed to Immunotherapy
Lead sponsor
Samsung Medical Center
Phase
Phase 2
Overall status
Not yet recruiting
Start date
August 31, 2026
Completion date
January 31, 2028
Enrollment
72 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

refractory solid cancer patients unexposed to immunotherapy